Aerovate Therapeutics, Inc. financial data

Symbol
AVTE on Nasdaq
Industry
Pharmaceutical Preparations
Location
930 Winter Street, Suite M 500, Waltham, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 709 % -39.3%
Debt-to-equity 16.4 % +70.7%
Return On Equity -90.2 % -63.2%
Return On Assets -77.5 % -53.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 28.9M shares +4.36%
Common Stock, Shares, Outstanding 28.9M shares +4.39%
Entity Public Float 232M USD +47.5%
Common Stock, Value, Issued 3K USD 0%
Weighted Average Number of Shares Outstanding, Basic 28.9M shares +4.42%
Weighted Average Number of Shares Outstanding, Diluted 28.9M shares +4.42%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 69.5M USD +18.5%
General and Administrative Expense 20.8M USD +25.5%
Operating Income (Loss) -90.3M USD -20%
Nonoperating Income (Expense) 1.17M USD -35%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -10.9M USD -292%
Net Income (Loss) Attributable to Parent -84.6M USD -20.6%
Earnings Per Share, Basic -2.98 USD/shares -8.76%
Earnings Per Share, Diluted -2.98 USD/shares -8.76%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 31.1M USD -3.31%
Cash, Cash Equivalents, and Short-term Investments 88.7M USD -34.4%
Assets, Current 90.6M USD -34.2%
Property, Plant and Equipment, Net 14K USD -95.6%
Operating Lease, Right-of-Use Asset 259K USD -63.7%
Other Assets, Noncurrent 81K USD -96.4%
Assets 91M USD -35.4%
Accounts Payable, Current 908K USD -74.1%
Employee-related Liabilities, Current 3.95M USD +49.3%
Liabilities, Current 10.3M USD -29.9%
Operating Lease, Liability, Noncurrent 81K USD -77.4%
Liabilities 10.5M USD -30.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax 224K USD
Retained Earnings (Accumulated Deficit) -228M USD -59.2%
Stockholders' Equity Attributable to Parent 80.5M USD -36%
Liabilities and Equity 91M USD -35.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -23.7M USD -107%
Net Cash Provided by (Used in) Financing Activities 471K USD +111%
Net Cash Provided by (Used in) Investing Activities 8.83M USD -42.6%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 28.9M shares +4.39%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -14.4M USD -444%
Deferred Tax Assets, Valuation Allowance 43.6M USD +87.2%
Deferred Tax Assets, Gross 43.8M USD +85.7%
Operating Lease, Liability 540K USD -33.3%
Depreciation 28K USD +33.3%
Payments to Acquire Property, Plant, and Equipment 16K USD -42.9%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -84.1M USD -20.9%
Lessee, Operating Lease, Liability, to be Paid 558K USD -34.5%
Operating Lease, Liability, Current 459K USD +1.77%
Lessee, Operating Lease, Liability, to be Paid, Year Two 242K USD -52.4%
Lessee, Operating Lease, Liability, to be Paid, Year One 242K USD +137%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 18K USD -58.1%
Lessee, Operating Lease, Liability, to be Paid, Year Three 242K USD -50.5%
Deferred Tax Assets, Operating Loss Carryforwards 16.2M USD +37.5%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 2.21M USD +123%
Lessee, Operating Lease, Liability, to be Paid, Year Four 242K USD
Operating Lease, Payments 127K USD +3.25%
Additional Paid in Capital 308M USD +14.5%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 206K USD -31.8%
Share-based Payment Arrangement, Expense 13.3M USD +28.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%